Founded in 2000 and based in Madison, Wisconsin, ioGenetics, LLC is a biotechnology company dedicated to designing and developing innovative solutions for infectious diseases. The company's core mission is to combat these diseases through advanced biotechnological approaches. Their product portfolio includes recombinant fusion protein antimicrobial drugs, anticryptosporidial proteins, and microbial peptide epitope target libraries, targeting a market focused on healthcare and disease prevention.
Notable figures affiliated with ioGenetics include leading scientists and researchers in the field of biotechnology. The company has attracted investment from prominent venture capital firms specializing in biotech innovations. Key achievements include the development of several proprietary protein products that have shown significant promise in preclinical trials. Overall, ioGenetics has made a substantial impact on the biotech industry by advancing the treatment options for infectious diseases and fostering partnerships for further research and development.
